Abcuro, Inc. has designed a cell depleting monoclonal antibody, specific for KLRG1 as a potential treatment strategy for certain autoimmune diseases in which KLRG1+ CD8+ cells have been identified as mediators of pathology. Here, KLRG1 is linked to autoimmune disease.